Literature DB >> 1455571

Karyometry in recurrent superficial transitional cell tumors of the bladder.

H G van der Poel1, R D van Caubergh, M E Boon, F M Debruyne, J A Schalken.   

Abstract

Transitional cell carcinoma of the bladder has a high recurrence rate after local treatment. Progression to a higher stage occurs in 10-30% of the recurrent tumors, and early detection of potentially progressive tumors is important. In the current study morphometric, densitometric, and chromatin textural features of nuclei of superficial bladder tumors (pTa-T1) were studied to determine the value of karyometric features in the prediction of tumor progression. Seventy-two histological samples from 36 patients, consisting of both the primary and the first recurrent superficial tumor, were analyzed. Patients were divided into two groups: those with tumor progression, defined as an increase in tumor stage or occurrence of metastatic disease, and those without. Discriminant analysis on four karyometric features resulted in correct prediction of prognosis of 78% and 97% in the primary and recurrent tumors, respectively (P < 0.001). Tumor grade and stage did not offer additional information concerning prognosis. Karyometric analysis of recurrent superficial transitional cell tumors can be useful in selecting patients who need a more aggressive therapy. However, tumor characteristics of recurrent tumors varied and continuous evaluation of the karyometric features is necessary for early detection of an increase in the malignant potential of the tumor.

Entities:  

Mesh:

Year:  1992        PMID: 1455571     DOI: 10.1007/bf00922753

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  28 in total

1.  Long-term follow-up of intravesical Epodyl therapy for superficial bladder cancer.

Authors:  G R Mufti; J S Virdi; M H Hall
Journal:  Br J Urol       Date:  1990-01

2.  Benign papilloma or papillary carcinoma of the bladder?

Authors:  L F Greene; K A Hanash; G M Farrow
Journal:  J Urol       Date:  1973-08       Impact factor: 7.450

3.  Clinical study of prognostic factors of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin.

Authors:  T Shinka; A Hirano; Y Uekado; T Ohkawa
Journal:  Br J Urol       Date:  1990-07

4.  The reproducibility of a quantitative grading system of bladder tumours.

Authors:  E C Ooms; A P Blok; R W Veldhuizen
Journal:  Histopathology       Date:  1985-05       Impact factor: 5.087

Review 5.  Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.

Authors:  M S Soloway; A M Jordan; W M Murphy
Journal:  Prog Clin Biol Res       Date:  1989

6.  Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone.

Authors:  K H Kurth; F H Schröder; U Tunn; R Ay; M Pavone-Macaluso; F Debruyne; M de Pauw; O Dalesio; F ten Kate
Journal:  J Urol       Date:  1984-08       Impact factor: 7.450

7.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.

Authors:  W Lutzeyer; H Rübben; H Dahm
Journal:  J Urol       Date:  1982-02       Impact factor: 7.450

8.  Superficial bladder cancer: progression and recurrence.

Authors:  N M Heney; S Ahmed; M J Flanagan; W Frable; M P Corder; M D Hafermann; I R Hawkins
Journal:  J Urol       Date:  1983-12       Impact factor: 7.450

9.  The value of morphometry and DNA flow cytometry in addition to classic prognosticators in superficial urinary bladder carcinoma.

Authors:  E C Blomjous; N W Schipper; J P Baak; W Vos; H J De Voogt; C J Meijer
Journal:  Am J Clin Pathol       Date:  1989-03       Impact factor: 2.493

10.  Diagnosis and grading of malignancy in squamous epithelial lesions of the larynx with DNA cytophotometry.

Authors:  A Böcking; W Auffermann; H Vogel; G Schlöndorff; R Goebbels
Journal:  Cancer       Date:  1985-10-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.